

HR 6717

Depression Side Effect Labeling Awareness Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 6, 2018

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Sep 6, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/6717>

Sponsor

Name: Rep. Rush, Bobby L. [D-IL-1]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 6, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 6, 2018)

Depression Side Effect Labeling Awareness Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug that has an increased risk of suicide or depression to prominently display such risk.

Actions Timeline

- **Sep 6, 2018:** Introduced in House
- **Sep 6, 2018:** Referred to the House Committee on Energy and Commerce.